Abstract
Rifampicin is a cornerstone of tuberculosis treatment, largely due to its sterilizing ability. Surprisingly, this article reported that the currently used daily dose of 600mg is likely not on the optimal part of the dose-response curve, and higher doses may be needed to achieve treatment shortening goals for drug-sensitive tuberculosis. This Recommendation is of an article referenced in an [http://f1000.com/prime/reports/m/4/12/...

This publication has 0 references indexed in Scilit: